Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced promising top-line results from a Phase 3 clinical trial assessing the effectiveness of Zepzelca® (lurbinectedin) combined with the PD-L1 inhibitor atezolizumab (Tecentriq®). This…
Qatar-WHO Report: Lessons and Recommendations for Healthier Sporting Events Building on the experiences from the FIFA World Cup Qatar 2022, the State of Qatar and the World Health Organization (WHO)…
Escalating Attacks on Healthcare Threaten Health Services in Lebanon Amid Conflict Since hostilities between Israel and Lebanon intensified on September 17, 2024, WHO has confirmed 23 attacks on healthcare in…
Strengthening the Shipping of Biological Specimens for Rapid Disease Detection and Response Since 2016, the WHO Global Influenza Program (GIP) has been supporting the United Nations Food and Agriculture Organization…
Influenza Virus Sharing Essential for Pandemic Preparedness: Yemen Achieves Milestone with WHO Collaboration Virus sharing is crucial for global pandemic preparedness, enabling the development of vaccine candidates, monitoring antiviral resistance,…
Elanco’s Parvovirus Antibody Treatment Saves Thousands of Puppies in First Year Elanco Animal Health has released the first real-world data showcasing the effectiveness of its Canine Parvovirus Monoclonal Antibody (CPMA),…
Lupin Launches First Generic Pred Forte® Ophthalmic Suspension in the U.S. Prednisolone Acetate Ophthalmic Suspension Marks First Generic Launch with 180-Day CGT Exclusivity Mumbai, Naples, October 15, 2024: Lupin Limited,…
Novotech, a full-service international clinical contract research organization (CRO), is proud to announce its recognition as a U.S. Great Place to Work® certified company. This prestigious certification underscores Novotech’s commitment…
bit.bio has successfully defended its European patent for the groundbreaking opti-ox™ technology, which facilitates the precise programming of pluripotent stem cells (PSCs), including induced pluripotent stem cells (iPSCs), into any…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative treatments for seizure disorders, announced the addition of a new patent to its intellectual property portfolio. The United States…
As part of a three-year, $30 million initiative focused on mental health and well-being, the Anthem Blue Cross and Blue Shield Foundation has launched a new program in Shenandoah County,…
PDUFA Goal Date Set for June 13, 2025: UGN-102 Could Be First FDA-Approved Treatment for LG-IR-NMIBC UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company committed to developing innovative solutions for…